Evidence map›Paper›PMID 33708770›Full record

ArticleFrontiers in cell and developmental biology2021

Establishment of Novel DNA Methylation-Based Prostate Cancer Subtypes and a Risk-Predicting Eight-Gene Signature.

Enchong Zhang, Fujisawa Shiori, Oscar YongNan Mu, Jieqian He, Yuntian Ge, Hongliang Wu, Mo Zhang, Yongsheng Song

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Enchong ZhangDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Fujisawa ShioriDepartment of Breast and Endocrine Surgery, Tohoku University Hospital, Sendai, Japan.
Oscar YongNan MuPANASIAUSMLE, Association of Asian Medical Graduates, Toronto, ON, Canada.
Jieqian HeDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Yuntian GeDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Hongliang WuDepartment of Spine and Joint Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Mo ZhangDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Yongsheng SongDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is the most common malignant tumor affecting males worldwide. The substantial heterogeneity in PCa presents a major challenge with respect to molecular analyses, patient stratification, and treatment. Least absolute shrinkage and selection operator was used to select eight risk-CpG sites. Using an unsupervised clustering analysis, called consensus clustering, we found that patients with PCa could be divided into two subtypes (Methylation_H and Methylation_L) based on the DNA methylation status at these CpG sites. Differences in the epigenome, genome, transcriptome, disease status, immune cell composition, and function between the identified subtypes were explored using The Cancer Genome Atlas database. This analysis clearly revealed the risk characteristics of the Methylation_H subtype. Using a weighted correlation network analysis to select risk-related genes and least absolute shrinkage and selection operator, we constructed a prediction signature for prognosis based on the subtype classification. We further validated its effectiveness using four public datasets. The two novel PCa subtypes and risk predictive signature developed in this study may be effective indicators of prognosis.

Indexed as

DNA methylationhypermethylationpredictive signatureprognosisprostate cancerRND3systems biology

Identifiers

PMID33708770
PMCPMC7940376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.